开发和表征交联k-carrageenan/sericin混合物与共价剂或热交联用于延长释放的印梅他辛
Wedja Timóteo Vieira1, Meuris Gurgel Carlos da Silva1, Laura de Oliveira Nascimento2
1University of Campinas, School of Chemical Engineering, Albert Einstein Av., 500, Cidade Universitária "Zeferino Vaz", Campinas, SP 13083-852, Brazil.
International journal of biological macromolecules
|July 1, 2023
概括
这项研究开发了用于修改药物释放的新型k-carrageenan/sericin颗粒,成功封装了印美他辛 (IND). 由此产生的颗粒显示了胃抵抗性和作为有效的药物输送载体的潜力.
科学领域:
- 材料科学 材料科学 材料科学
- 制药科学 制药科学
- 生物技术是生物技术.
背景情况:
- 修改释放药物递送系统对于最大限度地减少与即时释放口服药物相关的副作用和毒性至关重要.
- 在聚合物矩阵中封装药物提供了一种控制药物释放动力学和改善治疗结果的策略.
- k-Carrageenan和sericin是生物相容的聚合物,在药物输送系统中具有潜在的应用.
研究的目的:
- 在交联k-carrageenan/sericin (k-Car/Ser) 聚合物矩阵中使用共价和热方法封装Indomethacin (IND).
- 评估开发的交联聚合物颗粒的药物递送调制和物理化学性质.
- 为了评估在体外的药物释放特征,稳定性和生物相容性,印梅他辛载荷的颗粒.
主要方法:
- 通过共价和热交联,将印莫他辛 (IND) 封装到k-Car/Ser矩阵中.
- 颗粒的特征,包括形态,大小,捕获效率 (EE%) 和药物负载 (DL%).
- 在酸性 (pH1.2) 和生理性 (pH6.8) 条件下进行体外药物释放研究,稳定性评估和细胞活力测试 (中性红色和MTT).
主要成果:
- 获得了表面粗的球形粒子,平均直径为1.38-2.15毫米 (CCA) 和1.56-1.86毫米 (热).
- FTIR和X射线分析证实了IND的存在,并保持了其在粒子中的结晶性.
- 在PBS (pH 6.8) 中观察到药物释放高 (81-100%),在酸性介质中释放最小 (1.23-6.81%),表明胃抵抗.
- 配方在6个月内表现出稳定性,药物释放遵循与胀和链松的扩散机制.
- 装有IDM的粒子增强了细胞活力 (>75%的中性红色,>81%的MTT),表明良好的生物相容性.
结论:
- 开发的k-carrageenan/sericin/CMC颗粒表现出胃抵抗性和pH响应性药物释放特征.
- 这些配方显示出潜在的有效药物输送载体的印米他辛,提供受控释放和改善生物相容性.
- 交叉连接的聚合物矩阵成功调节了印梅他辛的释放,为减少治疗应用中的副作用铺平了道路.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...